Table 5 The wilcoxon test and the chi-square test analysis of risk factors for 30-days mortality
Characteristics (median[IQR] or n[%] | Non-survivors (n = 2) | Survivors (n = 15) | P value |
|---|---|---|---|
Age (years) | 9.50 (7.25–11.75) | 4.00 (3.00–7.00) | 0.204 |
Male | 0.00 (0.00%) | 11.00 (73.30%) | 0.110 |
PRISM | 13.50 (12.75–14.25) | 12.50 (10.00–15.00) | 0.808 |
PCIS | 83.00 (78.50–87.50) | 82.00 (80.00–89.50) | 1.000 |
Immunocompromised conditions | |||
 Use of corticosteroids | 1.00 (50.00%) | 6.00 (40.00%) | 1.000 |
 Use of immunosuppressive agents | 1.00 (50.00%) | 0.00 (0.00%) | 0.118 |
 Hematologic malignancies | 1.00 (50.00%) | 6.00 (40.00%) | 1.000 |
 Solid tumors | 1.00 (50.00%) | 6.00 (40.00%) | 1.000 |
 Rheumatic diseases | 0.00 (0.00%) | 2.00 (13.30%) | 1.000 |
 Indwelling gastric tube | 1.00 (50.00%) | 14.00 (93.30%) | 0.228 |
 Indwelling urinary catheter | 1.00 (50.00%) | 13.00 (86.70%) | 0.331 |
 Indwelling vein catheter | 2.00 (100.00%) | 13.00 (86.70%) | 1.000 |
 LDH (U/L) | 905.50 (901.75–909.25) | 630.00 (547.00–968.50) | 0.618 |
 CRP (mg/L) | 119.11 (67.51–170.70) | 57.32 (21.04–82.19) | 0.824 |
 PCT (ng/ml) | 1.05 (0.58–1.53) | 0.37 (0.23–0.49) | 1.000 |
 White blood cells (X 109/L) | 8.13 (6.07–10.18) | 4.20 (1.84–10.64) | 0.529 |
 Neutrophils (X 109/L) | 6.04 (3.45–8.64) | 3.18 (1.25–7.46) | 0.824 |
 Lymphocytes (X 109/L) | 0.56 (0.42–0.70) | 0.34 (0.09–1.17) | 0.824 |
 SMRNs in BALF | 68,781.00 (48,375.00–89,187.00) | 1269.50 (583.00–7147.75) | 0.030* |
 ARDS | 14.0 (82.4%) | 12 (80.0%) | 1.000 |
 Mechanical ventilation | 2.00 (100.00%) | 14.00 (93.30%) | 1.000 |
 Days of mechanical ventilation | 9.50 (8.25–10.75) | 7.00 (5.00–8.00) | 0.471 |
 LOS | 16.00 (15.50–16.50) | 13.00 (8.50–15.50) | 0.296 |
 LOS in PICU | 16.00 (15.50–16.50) | 10.00 (7.00–13.00) | 0.050* |